Treatment With Sandostatin in Patients With Castrate Resistance Prostate Cancer Showing Uptake of 68Ga-DOTATET
Status:
Unknown status
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
Purpose: Castrate resistance prostate cancer (CRPC) often shows histological evidence of
neuroendocrine differentiation (NED). Recently the investigators initiated a research project
investigating the uptake of the radiotracer 68Ga-DOTATET (a marker of neuroendocrine
tumors-NET) in PET/CT in patients with CRPC. In 4/8 patients studied thus far, uptake of the
tracer in bone metastases was found. It has been shown that monthly injections of
Somatostatin lengthen overall survival in patients with NET. The purpose of the current
project is to examine the ability of Somatostatin to stabilize or possibly reverse metastases
in patients with CRPC that express high level of somatostatin receptors in 68Ga-DOTATET
PET/CT.
Materials and Methods: 30 patients with CRPC will be studied with 68Ga-DOTATET PET/CT.
Patients showing uptake of the radiotracer 68Ga-DOTATET in at two least to metastases will be
considered eligible for the study. These patients will be evaluated biochemically and
clinically and will be treated with monthly injections of Sandoatatin LAR - 30mg. Clinical,
biochemical and imaging studies (68Ga-DOTATET PET/CT) will be repeated after 4 and 12 months
of treatment. Responding patients (stabilization or decrease in the number and SUV of
metastases) will be subjected to continued therapy until progression.